LabCorp rolled out its first-ever simultaneous test for detecting four major respiratory viruses, including COVID-19, ahead of an upcoming flu season that could put added strain on the healthcare system, the company announced in a press release on Tuesday.

The single-panel test will detect COVID-19, influenza A/B, and respiratory syncytial virus (RSV) to help doctors diagnose and treat patients more effectively during the ongoing coronavirus pandemic.

“The U.S. is facing the most challenging health crisis in a century and is about to enter flu season, which has the potential to put additional strain on our healthcare system and cost lives,” Dr. Brian Caveney, LabCorp Diagnostic’s chief medical officer and president, said in a statement.

Caveney added that patients infected with COVID-19, influenza A / B, or RSV, often exhibit similar symptoms such as cough, fever, chest tightness, and body aches, leading to “a potential surge of patients seeking testing.”

LabCorp, one of the world’s largest laboratory clinical networks, is also waiting for FDA authorization for its Pixel by LabCorp at-home test for the flu, COVID-19, or RSV.

LabCorp (LH) shares are currently trading at $175.55 a share, down 17 cents from Friday’s close.

The press release can be found here.